Genetic Deletion of mGlu3 Metabotropic Glutamate Receptors Amplifies Ischemic Brain Damage and Associated Neuroinflammation in Mice

Federica Mastroiacovo, Manuela Zinni, Giada Mascio, Valeria Bruno, Giuseppe Battaglia, Julien Pansiot, Tiziana Imbriglio, Jerome Mairesse, Olivier Baud, and Ferdinando Nicoletti

Background: Type-3 metabotropic glutamate (mGlu3) receptors are found in both neurons and glial cells and regulate synaptic transmission, astrocyte function, and microglial reactivity. Here we show that the genetic deletion of mGlu3 receptors amplifies ischemic brain damage and associated neuroinflammation in adult mice. An increased infarct size was observed in mGlu3−/− mice of both CD1 and C57Black strains 24 h following a permanent occlusion of the middle cerebral artery (MCA) as compared to their respective wild-type (mGlu3+/+) mice counterparts. Increases in the expression of selected pro-inflammatory genes including those encoding interleukin-1β, type-2 cyclooxygenase, tumor necrosis factor-α, CD86, and interleukin-6 were more prominent in the peri-infarct region of mGlu3−/− mice. In contrast, the expression of two genes associated with the anti-inflammatory phenotype of microglia (those encoding the mannose-1-phosphate receptor and the α-subunit of interleukin-4 receptor) and the gene encoding the neuroprotective factor, glial cell line-derived neurotrophic factor, was enhanced in the peri-infarct region of wild-type mice, but not mGlu3−/− mice, following MCA occlusion. In C57Black mice, the genetic deletion of mGlu3 receptors worsened the defect in the paw placement test as assessed in the contralateral forepaw at short times (4 h) following MCA occlusion. These findings suggest that mGlu3 receptors are protective against ischemic brain damage and support the way to the use of selective mGlu3 receptor agonists or positive allosteric modulators in experimental animal models of ischemic stroke.

Keywords: focal ischemia, knockout mice, neuroinflammation, pro-inflammatory genes, mGlu3 receptors
INTRODUCTION

Ischemic stroke is the second cause of mortality and disability worldwide due to the lack of effective therapies besides intravenous thrombolysis, which is restricted to selected patients and useful only in a short therapeutic window. Understanding the mechanisms underlying neuronal vulnerability to ischemic damage may pave the way to novel therapeutic strategies in cerebrovascular disorders. In the area close to the occluded vessel, two distinct zones can be distinguished: the core (a zone of severe ischemia and neuronal death) and the penumbra (a zone of moderate ischemia) (1). Up to few hours following the vessel occlusion, the size of both areas is almost equivalent (2); however, as the ischemic injury progresses, the penumbra becomes the main affected area (3), in which the neurons are still salvageable with appropriate interventions. Excitotoxicity, oxidative stress, neuroinflammation, mitochondrial damage, and lack of neuroprotective factors are the established mechanisms of ischemic neuronal damage (4–8). These mechanisms are shaped by metabotropic glutamate (mGlu) receptors, which are G-protein coupled receptors activated by glutamate.

mGlu receptors form a family of eight subtypes, subdivided into three groups on the basis of their primary sequence homology and transduction mechanisms. Group I comprises mGlu1 and mGlu5 receptors, which are coupled to Gq/11 proteins. Their activation leads to phosphatidylinositol-4,5-bisphosphate hydrolysis, with ensuing formation of inositol-1,4,5-trisphosphate and diacylglycerol. Group II (mGlu2 and mGlu3) and group III (mGlu4, -6, -7, and -8) receptors are coupled to Gi/o proteins in heterologous expression systems (9). Most of these subtypes are found in neurons, astrocytes, and microglia and regulate many features of the tetrapartite synapse formed by presynaptic terminals, postsynaptic elements, and surrounding astrocytes and microglia.

Early studies of mGlu2 and mGlu3 receptors (10, 11) did not differentiate between the two subtypes because of the lack of selectivity of orthosteric agonists and the belief that the function of the two receptors was similar. Using both genetic and subtype-selective pharmacological tools, it is now clear that mGlu2 and mGlu3 receptors are functionally different and may have an opposite impact on the mechanisms of neurodegeneration/neuroprotection. While both subtypes are presynaptically localized and negatively modulate neurotransmitter release, mGlu3 receptors are also found in post-synaptic elements, and their activation boosts mGlu5 receptor signaling (12, 13). In addition, activation of mGlu2 receptors drives microglial cells toward a pro-inflammatory/neurotoxic phenotype (14, 15), whereas activation of mGlu3 receptors induces an anti-inflammatory phenotype (16). In addition, mGlu3 receptors (but not mGlu2 receptors) are present in astrocytes, and their activation stimulates the production of neurotrophic factors (17, 18). Using the four-vessel occlusion model of transient global ischemia in rats, we have shown that selective pharmacological activation of mGlu2 receptors amplified hippocampal damage, whereas mGlu2 receptor blockade was neuroprotective (19). Similar findings were obtained using mice lacking mGlu2 receptors, in which the infarct size was enhanced in response to transient focal ischemia (20). To our knowledge, there are no studies on mGlu3 receptors and brain ischemia, although the selective activation of mGlu3 receptors was shown to be neuroprotective in in vitro studies (17, 21–24).

Here we used two different strains of mice to examine whether the genetic deletion of mGlu3 receptors affects brain damage and associated neuroinflammation induced by the permanent occlusion of the middle cerebral artery (MCA).

MATERIALS AND METHODS

Animals

Wild-type mice (mGlu3+/+) or mGlu3−/− mice on C57Black genetic background (22) and wild-type mice (mGlu3+/+) or mGlu3−/− mice on CD1 genetic background (25) were generated by homozygous breeding (in-house production). Adult male mice weighing 25 g were housed under controlled conditions (ambient temperature, 22°C; humidity, 40%) on a 12-h light–dark cycle with food and water ad libitum. Studies were performed in agreement with the national and international guidelines and regulations on animal care and use and were approved by the Neurmed Institutional Animal Care and Use Committee and by the Italian Ministry of Health. All efforts were made to minimize animal suffering and to reduce the number of animals used.

Permanent Focal Ischemia in Mice

Permanent focal cerebral ischemia was induced by distal electrocauterization of the MCA (26–28). The mice were anesthetized with chloral hydrate (400 mg/kg, i.p.), and an incision was made between the outer canthus of the eye and the external auditory meatus. The temporal muscle was bisected to expose the skull, and the MCA was exposed by means of burr-hole craniotomy carried out by using a surgical drill. A thin layer of bone was preserved to protect the dura mater and the cortical surface against mechanical damage and thermal injury, while the remaining bone was gently removed. The MCA was occluded by electrocaugetation, and the muscle and then the skin incision were sutured. A rectal temperature probe connected to a heating pad was used to maintain body temperature at 37°C throughout the surgical period. After surgery, the mice did not receive anti-inflammatory drugs or antibiotics, were placed in an incubator (compact incubator, Thermo Scientific, AHSI, Bernaggio, MI, Italy) at 37°C for 2, and then placed back into their home cages. The functional deficit was assessed with the paw placement test before ischemia and after 4 and 24 h by an operator who was unaware of the genotype. The animals were killed 24 h after ischemia, and their brains were processed for histological or mRNA analysis.

Paw Placement Test

Paw placement test provides information on the tactile/proprrioceptive response to limb stimulation. The animals were placed with all paws on a surface in horizontal position, and the head was held at 45° angle so that visual stimulation was prevented. The paws to be tested were pushed...
along the edge in order to lose contact with the table surface. The ability of the animals to place the limb back onto the table surface when the mice was moved toward the edge was evaluated. A score was used as follows: 1—prompt placement of the limb onto the table, 0.5—incomplete or delayed placing of the limb; and 0—no placing with the extension of the limb and paw (29).

**Histology**

The mice were sacrificed 24 h after MCA occlusion, and the brains were fixed in Carnoy’s solution, embedded in paraffin, and sectioned at 10 μm. The sections were deparaffinized and processed for staining with thionin (Nissl staining) for histological assessment of neuronal degeneration. The analysis was carried out on sections regularly spaced every 550 μm through the extension of the ischemic region. This space interval corresponds to a standardized procedure, allowing one to measure the ischemic brain volume based on 10 slides. The infarct area was outlined at a magnification of ×2.5, and it was quantified using Scion Image software (NIH, Bethesda, MD, USA). Then, the volume was calculated by integrating the cross-sectional area of damage on each stained section and the distance between them (20, 30).

**Immunohistochemistry**

Brain sections were deparaffinized, after antigen retrieval, in citrate buffer (10 mM sodium citrate, pH 6.0) for 30 min. The sections were pretreated with 0.3% H2O2 for 10 min to block endogenous peroxide activity after incubation with 6% normal serum and 0.1% Triton-X100 in PBS for 2 h. The sections were incubated with the following primary antibodies: anti-Cox2 (1:200, Abcam, Cambridge, UK) or anti-Iba1 (1:1,000, Wako Chemicals, Osaka, Japan). The samples were rinsed and incubated for 2 h at room temperature with secondary biotinylated anti-rabbit horse antibodies (1:200, Vector Laboratories, Burlingame, CA) followed by streptavidin alexa fluor 488 (1:200, Molecular Probes, Carlsbad, CA). Finally, the sections were mounted with Hard Set Vectashield with Dapi (Vector Laboratories, Burlingame, CA). Iba1 immunostaining was detected with a Zeiss 780 confocal laser scanning microscope. Cox-2 immunostaining was detected with a Zeiss Axio-photo 2 optic microscope. Cell counting was performed in three coronal sections for mouse at ×20 magnification.

**RNA Purification, cDNA Synthesis, and Real-Time qPCR**

The mice were killed 24 h after MCA occlusion, and the brains were quickly removed. The brains were cut with a matrix, and a 3-mm region along the rostral-caudal axis from 1.54 mm anterior to 1.58 mm posterior to the bregma was sliced. Each slice was further punched to dissect a square region (1 × 1.3 mm) corresponding to the ischemic core, the dorsomedial portion of the peri-infarct region or the corresponding region of the contralateral side (highlighted in Figures 2A, 4A). The samples were immediately frozen on liquid nitrogen and stored at −80°C. Total RNA was extracted using Nucleozol reagent and the NucleoSpin RNA Set for NucleoZol (Macherey-Nagel, Hoerdt, France) according to the manufacturer’s instruction. RNA quantity and quality were determined using the NanodropTM apparatus (Thermofisher Scientific, Walthman, MA), and 0.5 μg of total RNA was used to perform a reverse transcription (IscriptTM cDNA synthesis kit, Bio-Rad, Marnes-la-Coquette, France). The qPCR measurements were performed in triplicate using SYBR Green Super-mix (Bio-Rad, Marnes-la-Coquette, France). The reaction conditions were as follows: 98°C for 30 s (polymerase activation), followed by 40 cycles at 95°C for 5 s, 60°C for 10 s, and 72°C for 10 s. The primers were designed using Primer3Plus software (Table 1). A melting curve analysis was used to assess the specificity of the selected primers, and the results were quantified using relative standard curve methods. The target gene relative expression in the dorsomedial peri-infarct regions and their respective contralateral sides was calculated after normalization to the ribosomal protein L13 (Rpl13) reference gene. The following reference genes—RP113, Hmbs, and Rn18s—were assessed in the core area and its respective contralateral side. Data are expressed as mean ± SEM and normalized to the mGlu3+/+ contralateral group.

**Statistical Analysis**

Statistical analysis of all data was performed using GraphPad PRISM software, version 8.0. In all experiments, data are presented as means ± standard error of the mean (SEM), and p <0.05 was considered significant. A two-tailed unpaired Student’s t-test was performed for two-group comparisons in infarct volume. The mRNA data were normalized to the wild-type contralateral group and analyzed using two-way ANOVA, followed by Fisher’s post hoc comparison tests. For behavioral analysis, the non-parametric Mann–Whitney U test and Friedman ANOVA were performed.

---

**TABLE 1 | Gene primers.**

| Gene   | Forward                  | Reverse                  |
|--------|--------------------------|--------------------------|
| Arg1   | GGTAAAGGAACCCACCGTGCTTG | GCCCAAGATGCTCTCGAACTG    |
| Cdb6   | GAGCAGGATGATGAACTG     | GGCTCTCCTGCTGCTGCTG     |
| Gdnf   | GCAACCCCGGATTTCGGA     | AGCGTGGACCCCGAAGATTT    |
| Hmbs   | TCCCTGCTGACCAAAGAAAGAGT| GGGATGTTCTGGCTCTTGTTT   |
| Il1b   | GAAGATGGAAAAAGCATTTG   | GTACAGTTGGGAGAATCTGCG   |
| Il6    | CAACAGCAGTCGTTCAAG     | GGCCACCTCTGCTCTGACGCG   |
| Il4a   | GGATAAGCAGACCGAAAGCC   | ACTCTGCGAGACTTTGTTG     |
| Mc1    | CTTGGGGGGAAATGAATACT   | TAAGAGACGCGTTGGTTGA     |
| Ptgds2 | TACACTCACAAGAAAGATTTGCTTTCTCTGCTTGA | AACGCTGCTGCTGACTATT |
| TGFb   | GGATGACGTTGGAAT       | CCAGTTGGGAGCATATTAGCTC  |
| Tnfα   | GCCCTTCTCCATTTCTCTTCTC| GAGTCGTTGCTCTGAGAGA     |
| Tgα    | TGATGACGCTGAGCTGGCTTCTCTGCTTGA | CACAAGAGACGAGGGCTGAA  |

Using Nucleozol reagent and the NucleoSpin RNA Set for NucleoZol (Macherey-Nagel, Hoerdt, France) according to the manufacturer’s instruction. RNA quantity and quality were determined using the NanodropTM apparatus (Thermofisher Scientific, Walthman, MA), and 0.5 μg of total RNA was used to
RESULTS
Genetic Deletion of mGlu3 Receptors Enhanced Infarct Size and Neuroinflammation in CD1 Mice Undergoing Permanent MCA Occlusion

Ischemic infarct caused by permanent distal MCA occlusion in CD1 mice included the primary motor cortex (M1), the forelimb (S1FL), dysgranular (S1DZ), and upper lip (S1ULp) regions of the primary somatosensory cortex, the secondary somatosensory cortex (S2), and the granular/dysgranular insular cortex (GI/DI) (Figure 1). The ischemic infarct was detectable as early as 2 h after MCA occlusion and reached its maximal size at 24 h. The extent of the infarct volume, evaluated by Nissl staining at 24 h after MCA occlusion, was greater in mGlu3−/− mice compared to their mGlu3+/+ counterparts (Figures 2A,B). We measured the transcripts of three housekeeping genes (Hmbs, Rn18s, and Rpl13) in a small region of the ischemic core (highlighted in Figure 2C) as an unbiased method to detect cell damage in response to permanent ischemia. In mGlu3+/+ mice, the mRNA levels of the three transcripts were significantly reduced in the ischemic core with respect to the corresponding region of the contralateral hemisphere. The reduction was much greater in the ischemic core of mGlu3+/+ mice (Figure 2D). Interestingly, gene expression was also lower in the contralateral site of mGlu3−/− mice compared to the contralateral site of mGlu3+/+ mice (Figure 2D).

To examine whether the genetic deletion of mGlu3 receptors amplified neuroinflammation in response to MCA occlusion, we first performed immunofluorescent staining of the microglia/macrophage marker Iba1 (31) in the peri-infarct region and the corresponding contralateral region (Figure 3A). The density of Iba1+ cells (measured in three microscopic sections) was greater in the peri-infarct regions of mGlu3−/− mice as compared to the peri-infarct region of mGlu3+/+ mice (Figure 3B). The mGlu3−/− mice also showed a trend to an increased density of Iba1+ cells in the contralateral region (Figure 3B). We then measured the transcripts of a number of pro-inflammatory, immune-modulatory, and anti-inflammatory genes in the dorsomedial peri-infarct and contralateral regions (dissected as shown in Figure 4A). There was no difference in the expression of the housekeeping gene Rpl13 between the ipsilateral and contralateral sides in the two genotypes, suggesting the lack of cell death in the peri-infarct region (Figure 4B). In mGlu3+/+ mice, the transcripts of Il1b, Ptgs2, and Tnfa genes encoding the proinflammatory cytokines, IL-1β, COX-2, and TNF-α, showed a significant increase in the peri-infarct region compared to the corresponding contralateral...
FIGURE 2 | Infarct size and expression of housekeeping genes in the infarct core of CD1 mGlu3+/+ and mGlu3−/− mice subjected to permanent middle cerebral artery (MCA) occlusion. Nissl staining of sequential coronal brain sections of mGlu3+/+ and mGlu3−/− mice 24 h following MCA occlusion is shown in (A). Quantification of the infarct volume is shown in (B), where values are means ± S.E.M. of 11–13 mice per group. *p < 0.05 vs. mGlu3+/+ mice (Student’s t test; t = 2.967). The infarct core region dissected for measurements of housekeeping genes is indicated in (C). Hmbs, Rn18s, and Rpl13 mRNA levels in the ipsilateral and contralateral sides of the two genotypes are shown in (D), where values are means ± S.E.M. of five determinations. *p < 0.05 (two-way ANOVA + Fisher’s least significant difference) vs. the contralateral side of the same genotype (+) or the corresponding side of mGlu3+/+ mice (#). Hmbs: genotype, F1,16 = 19.34, p = 0.0004; side, F1,16 = 24.67, p = 0.0001; interaction, F1,16 = 1.396, p = 0.2546; Rn18s: genotype, F1,16 = 17.48, p = 0.0007; side, F1,16 = 88.85, p < 0.0001; interaction, F1,16 = 1.086, p = 0.3167; Rpl13: genotype, F1,16 = 12.73, p = 0.0026; side, F1,16 = 243.3, p < 0.0001; interaction, F1,16 = 0.0936, p = 0.7636.

region, whereas the transcripts of Cd86 and Il6, encoding CD86 and IL-6, respectively, were unchanged (Figure 4B). In contrast, the expression of all five pro-inflammatory genes was largely increased in the peri-infarct region of mGlu3−/− mice, compared to the corresponding contralateral region (Figure 3B). Remarkably, the Ptgs2, Tnfa, Cd86, and Il6 mRNA levels were significantly higher in the peri-infarct region of mGlu3−/− mice with respect to the peri-infarct region of mGlu3+/+ mice, and a trend to increase was also observed for the transcript encoding IL-1β (Figure 4B). Changes in COX-2 immunostaining paralleled the changes of the Ptgs2 transcript (greater density of COX-2+ cells in both sides of mGlu3−/− mice), although the differences were not statistically significant (Figures 4C,D).

The expression of three immunomodulatory genes (Mrc1, Il4ra, and Socs3, encoding MRC-1, IL4Ra, and SOCS3, respectively) largely increased in the peri-infarct region of mGlu3+/+ mice, whereas only the transcript encoding
SOCS3 increased in the peri-infarct region of mGlu3<sup>−/−</sup> mice as compared to the contralateral corresponding region (Figure 5A). Mrcl expression was lower in the ipsilateral side of mGlu3<sup>−/−</sup> mice as opposed to what was found in mGlu3<sup>+/+</sup> mice. Interestingly, however, the Mrcl mRNA levels were significantly higher in both sides of mGlu3<sup>−/−</sup> mice with respect
FIGURE 4 | Expression of pro-inflammatory genes in the peri-infarct region and the corresponding contralateral region of CD1 mGlu3+/+ and mGlu3−/− mice subjected to middle cerebral artery (MCA) occlusion. The anatomical location of the dissected dorsomedial peri-infarct region and the corresponding contralateral region is shown in (A). The mRNA levels of the selected housekeeping and pro-inflammatory genes of the ipsilateral and contralateral sides of mGlu3+/+ and mGlu3−/− mice subjected to MCA occlusion is shown in (B). Values are means ± S.E.M. of five determinations. p < 0.05 (two-way ANOVA + Fisher’s least significant difference) vs. the contralateral side of the same genotype (*) or the corresponding side of mGlu3+/+ mice (#). Rpl13: genotype, F1,16 = 3.652, p = 0.0741; side, F1,16 = 0.6079, p = 0.4470; interaction, F1,16 = 0.1461, p = 0.7074; Il1b: genotype, F1,16 = 15.26, p = 0.0013; side, F1,16 = 18.79, p = 0.0005; interaction, F1,16 = 1.756, p = 0.2038; Tnfa: genotype, F1,16 = 1.11, p = 0.3078; Cd86: genotype, F1,16 = 8.926, p = 0.048; side, F1,16 = 12.82, p = 0.0027; interaction, F1,16 = 0.0012, p = 0.97; Il6: genotype, F1,16 = 4.584, p = 0.048; side, F1,16 = 4.584, p = 0.048; interaction, F1,16 = 2.142, p = 0.1627; Ptgs2: genotype, F1,16 = 10.09, p = 0.0012; side, F1,16 = 17.54, p = 0.0007; interaction, F1,16 = 0.0012, p = 0.97. Representative COX-2 immunostaining in the peri-infarct regions of the mGlu3+/+ and mGlu3−/− mice is shown in (C). The density of COX-2-expressing cells in three sections of the peri-infarct and contralateral regions of the two genotypes is shown in (D), where values are means ± S.E.M. from four mice per group. Statistical analysis was performed by two-way ANOVA + Fisher’s least significant difference. Genotype, F1,14 = 2.284, p = 0.1529; side, F1,14 = 2.006, p = 0.1785; interaction, F1,14 = 0.001865, p = 0.966. Scale bar = 25 µm.
to the corresponding regions of mGlu3+/+ mice (Figure 5A). The Soc3 mRNA levels increase to a greater extent in the peri-infarct region of mGlu3−/− mice than in the peri-infarct region of mGlu3+/+ mice (Figure 5A).

The expression of the anti-inflammatory gene Arg1 (encoding arginase-1) did not differ between the ipsilateral and contralateral sides of mGlu3+/+ mice after MCA occlusion. In mGlu3−/− mice, the Arg1 mRNA levels showed a large increase in the ipsilateral side. In addition, the levels were lower in the contralateral side and higher in the ipsilateral side with respect to the corresponding regions of mGlu3+/+ mice (Figure 5A).

Using the same extracts from the peri-infarct region, we extended the analysis to two trophic factors (GDNF and TGF-β), which are under the control of mGlu3 receptors. Interestingly, the transcript encoding GDNF was exclusively increased in the peri-infarct region of mGlu3+/+ mice, whereas the transcript encoding TGF-β was increased in the peri-infarct region of mGlu3−/− mice (Figure 5B).

**DISCUSSION**

The role of mGlu receptors in mechanisms of ischemic neuronal cell death has been the subject of extensive investigation. Pharmacological blockade of mGlu1 receptors was shown to be neuroprotective in hippocampal slices subjected to a paradigm of oxygen/glucose deprivation and in models of transient global ischemia (32, 33). Conversely, the activation of mGlu1 receptors was found to mediate ischemic tolerance induced by “ischemic preconditioning” in hippocampal slice preparations (34). However, these findings have not been translated into effective treatment strategies in stroke because mGlu1 receptors may display neurotoxic and neuroprotective functions depending on the cell context and the paradigm of neuronal death (35, 36). The use of mGlu5 receptor ligands in stroke models has generated conflicting results. Early studies showed that both mGlu5 receptor agonists and antagonists reduced infarct size in a rat intraluminal filament model of transient MCA occlusion (37), whereas pharmacological activation of mGlu5 receptors was not protective in the endothelin-1 rat model of focal ischemia (38). More recent findings showed that selective pharmacological blockade of mGlu5 receptors reduced microglial activation and neuronal death induced by acute intracerebral hemorrhage (39). The mGlu4 receptors are also potential drug targets for neuroprotection in ischemic stroke as shown by the evidence that mGlu4 receptor activation reduced infarct size in ischemic mice and rats, whereas brain damage was amplified in mGlu4−/− mice (40). Activating mGlu4 receptors might also restrain immune reactive mechanisms in stroke (6) by promoting immune tolerance (41).

Our data offer the first evidence for a neuroprotective activity of mGlu3 receptors against focal brain ischemia in two different strains of mice. mGlu2 and mGlu3 receptors show a high degree of primary sequence homology, are both coupled to G_{i/o} proteins in heterologous expression systems, and share some functional properties including, for example, the ability to restrain neurotransmitter release (9). However, using both genetic and selective pharmacological tools, we were able to demonstrate that activation of mGlu2 receptors amplifies brain damage in rodent models of global and focal ischemia (19, 20). Thus, a comparison between present findings and previous data reveals that mGlu3 and mGlu2 receptors have an opposite impact on vulnerability to ischemic brain damage. There are at least two functions of mGlu3 receptors that account for this difference: the anti-inflammatory action in microglia (14, 16, 42) and the stimulation of TGF-β and GDNF production in astrocytes and neurons, respectively (21–23, 43, 44). We have found that gestational low-protein diet (LPD) combined with IL-1β injection in rat pups (modeling intrauterine growth restriction and perinatal brain inflammation in human neonates) was associated with a selective down-regulation of mGlu3 receptors in microglia. In addition, microglia reactivity to inflammatory challenge induced by LPD/IL-1β was reduced by the pharmacological activation of mGlu3 receptors, whereas pharmacological blockade or the genetic deletion of mGlu3 receptors induced...
FIGURE 5 | Expression of immunoregulatory, anti-inflammatory, and neuroprotective genes in the peri-infarct region of CD1 mGlu3+/+ and mGlu3−/− mice subjected to middle cerebral artery (MCA) occlusion. The mRNA levels of the selected immunoregulatory and anti-inflammatory genes of the ipsilateral and contralateral sides of wild-type and mGlu3−/− mice subjected to MCA occlusion is shown in (A). The mRNA levels of the genes encoding GDNF and TGF-β are shown in (B). Values are means ± S.E.M. of five determinations. p < 0.05 (two-way ANOVA + Fisher’s LSD) vs. the contralateral side of the same genotype (*) or the corresponding side of mGlu3+/+ mice (#). Arg1: genotype, $F_{1,16} = 0.2441, p = 0.628$; side, $F_{1,16} = 3.639, p = 0.0746$; interaction, $F_{1,16} = 14.98, p = 0.0014$; Mrc1: genotype, $F_{1,16} = 43.5, p < 0.0001$; side, $F_{1,16} = 0.1896, p = 0.6691$; interaction, $F_{1,16} = 11.97, p = 0.0032$; Il4ra: genotype, $F_{1,16} = 0.037, p = 0.848$; side, $F_{1,16} = 20.81, p = 0.0033$; interaction, $F_{1,16} = 11.19, p = 0.0041$; Socs3: genotype, $F_{1,16} = 4.619, p = 0.0473$; side, $F_{1,16} = 22.29, p = 0.0002$; interaction, $F_{1,16} = 1.413, p = 0.252$; Gdnf: genotype, $F_{1,16} = 16.19, p = 0.001$; side, $F_{1,16} = 5.731, p = 0.029$; interaction, $F_{1,16} = 3.118, p = 0.0966$; Tgfb: genotype, $F_{1,16} = 3.771, p = 0.0472$; side, $F_{1,16} = 3.18, p = 0.093$; interaction, $F_{1,16} = 4.621, p = 0.0472$.

an inflammatory phenotype in microglia (16). In contrast, mGlu2 receptor activation promotes a pro-inflammatory and neurotoxic phenotype in microglia (14, 15). The large increase in the expression of pro-inflammatory genes found in the peri-infarct region of mGlu3−/− mice strengthens the hypothesis that mGlu3 receptors are key regulators of microglial function and act to restrain neuroinflammation. This mechanism may critically shape neuronal vulnerability to focal ischemia because neuroinflammation caused by the activation of resident microglia and infiltration of peripheral monocytes is consistently associated with ischemic stroke, leading to secondary injury cascade and neuronal death (45–49).

The reduced expression of Mrc1 (vs. the contralateral side) and Il4ra (vs. mGlu3+/+ mice) found in the peri-infarct region of mGlu3−/− mice is consistent with a putative anti-inflammatory action of mGlu3 receptors. Mrc1 encodes mannose receptor 1, also referred to as CD206, which is involved in the mechanisms of pinocytosis and phagocytosis and is associated with the anti-inflammatory and neuroprotective phenotype in microglia (50–53). Il4ra encodes the α-subunit of the IL-4 receptor, which mediates the anti-inflammatory effect of IL-4 in macrophages and microglia (54, 55). Alternatively, the increased expression of Arg1 was found exclusively in the peri-infarct region of mGlu3−/− mice. Arg1 encodes for arginase 1, the
FIGURE 6 | Infarct size and performance in the paw placement test of C57Black mGlu3+/+ and mGlu3−/− mice subjected to permanent middle cerebral artery (MCA) occlusion. Nissl staining of sequential coronal brain sections of mGlu3+/+ and mGlu3−/− mice 24 h following MCA occlusion is shown in (A). Quantification of the infarct volume is shown in (B), where values are means ± S.E.M. of 13–16 mice per group. *p < 0.05 vs. mGlu3+/+ mice (Student’s t test; t = 3.501). The paw placement scores of the contralateral and ipsilateral forepaws are shown in (C,D), respectively. Means ± S.E.M. are indicated. Contralateral side: *p < 0.05 vs. the corresponding basal values (time 0) (Friedman non-parametric ANOVA test + Dunn’s; Friedman statistical value = 20.65) or #p < 0.05 vs. values of mGlu3+/+ mice at 4 h (one-tailed Mann–Whitney non-parametric test).
enzyme that converts arginine into L-ornithine and is considered a marker for the anti-inflammatory phenotype of microglia. Accordingly, L-arginine is the same substrate for both nitric oxide synthase (NOS) and arginase 1, and the Arg1 outcompetes inducible NOS to reduce the production of nitric oxide (56). The STAT6 (type-6 Signal Transduction and Activator of Transcription)/Arg1 pathway promotes microglia/macrophage efferocytosis (phagocytosis of dying/dead cells), thus facilitating the resolution of inflammation and preventing further cell death in mice subjected to MCA occlusion (57, 58). The increased Arg1 expression detected in the peri-infarct region of mGlu3−/− mice might reflect a compensatory mechanism aimed at restraining the neuroinflammation, mediated by M2 microglia polarization (57, 58). The increase in SOCS3 transcript seen in mGlu3−/− mice might be a component of this compensatory mechanism because SOCS3 inhibits cytokine receptor signaling, although SOCS3 has pleiotropic activities and might be detrimental for cell survival via the induction of the pro-apoptotic metabolite, ceramide (59).

Studies performed in cell cultures and living mice have shown that the pharmacological activation of mGlu3 receptors stimulates the production of TGF-β in astrocytes (21–23) and GDNF in neurons (43, 44). Both GDNF and TGF-β are neuroprotective, and GDNF requires TGF-β for its neuroprotective action (60). The reduced GDNF transcript levels found in the peri-infarct region of mGlu3−/− mice are in line with the evidence that activation of mGlu3 receptors enhances GDNF production in the CNS (43, 44). Lowered GDNF levels might contribute to the increased infarct size in mGlu3−/− mice because GDNF is known to exert a neuroprotective activity.

In contrast, the increase in TGF-β mRNA levels found in the peri-infarct region of mGlu3−/− mice was unexpected because mGlu3 receptor activation is known to stimulate TGF-β production in astrocytes (17). One explanation is that, other cells, such as macrophages and microglia, are the source of TGF-β in the peri-infarct region of mGlu3−/− mice. How changes in TGF-β in gene transcripts contribute to mechanisms of neurodegeneration/neuroprotection in the peri-infarct region is unknown. However, a causal relationship may exist between the increase in TGF-β and the reduction in Mrc1 in the peri-infarct region of mGlu3−/− mice because TGF-β negatively modulates Mrc1 expression (61, 62).

Behavioral analysis performed in C57Black mice showed a greater defect in the paw placement test in mGlu3−/− mice at short times (4 h) following MCA occlusion. This might reflect the early brain damage and hyperinflammation caused by the lack of mGlu3 receptors. However, the performance in the paw placement test partially recovered, and there was no difference between mGlu3+/+ and mGlu3−/− mice at 24 h. An increased glutamate release caused by the lack of presynaptic mGlu3 receptors might contribute to excitotoxic neuronal death but, on the other side, might facilitate functional recovery by inducing mechanisms of activity-dependent synaptic plasticity. This hypothesis warrants further investigation.

In conclusion, our data suggest that the endogenous activation of mGlu3 receptors display a protective activity against ischemic brain damage and associated neuroinflammation and lays the groundwork for the use of subtype-selective mGlu3 receptor agonists or positive allosteric modulators (PAM) in experimental animal models of stroke. A selective mGlu3 receptor agonist is already available (63), and mGlu3 receptor PAMs are under development (64). These are putative drug candidates as neuroprotectants in ischemic stroke.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The animal study was reviewed and approved by Neuromed Institutional Animal Care and Use Committee and the Italian Ministry of Health. Written informed consent was obtained from the owners for the participation of their animals in this study.

AUTHOR CONTRIBUTIONS

FM: conceptualization, investigation, and formal analysis. MZ, GM, JP, and TI: investigation. VB, GB, JM, OB, and FN: supervision, data curation, and writing. All authors contributed to the article and approved the submitted version.

FUNDING

Ricerca Corrente 2021 funded by Italian Ministry of Health.

REFERENCES

1. Rossi DJ, Brady JD, Mohr C. Astrocyte metabolism and signaling during brain ischemia. Nat Neurosci. (2007) 10:1377–86. doi: 10.1038/nn2004
2. Ginsberg MD. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis lecture. Stroke. (2003) 34:214–23. doi: 10.1161/01.STR.0000084846.09677.62
3. Zhao W, Belayev L, Ginsberg MD. Transient middle cerebral artery occlusion by intraluminal suture: II. Neurological deficits, and pixel-based correlation of histopathology with local blood flow and glucose utilization. J Cereb Blood Flow Metab. (1997) 17:1281–90. doi: 10.1097/00004467-199712000-00003
4. Choi DW. Methods for antagonizing glutamate neurotoxicity. Cerebrovasc Brain Metab Rev. (1990) 2:105–47.
5. Friberg H, Wieloch T. Mitochondrial permeability transition in acute neurodegeneration. Biochimie. (2002) 84:241–50. doi: 10.1016/S0300-9084(02)01381-0
6. Iadecola C, Anrather J. Stroke research at a crossroad: asking the brain for directions. Nat Neurosci. (2011) 14:1363–8. doi: 10.1038/nn.2953
7. Khoshnam SE, Winlow W, Farzaneh M, Farbood Y, Moghaddam HF. Pathogenic mechanisms following ischemic stroke. Neurol Sci. (2017) 38:1167–86. doi: 10.1007/s10072-017-2938-1
24. Battaglia G, Solorgiu I, Gurasoiu O, Sestiliu F, Tomczak K, et al. Cell death mechanisms in stroke and novel molecular and cellular treatment options. Curr Neuropharmacol. (2018) 16:1396–415. doi: 10.2174/1570159X16666180321115544
23. Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti E, Schoepf DD, et al. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology. (2011) 60:1017–41. doi: 10.1016/j.neuropharm.2010.10.022
22. Bond A, Ragumooorthy N, Monn JA, Hicks CA, Ward MA, Lodge D, et al. LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia. Neurosci Lett. (1999) 273:191–4. doi: 10.1016/S0304-3940(99)00663-1
21. Bruno V, Sureda FX, Storto M, Casabona G, Caruso A, Knopfel T, et al. The use of the short-term outcome of cerebral transient focal ischemia. J Neurol Sci. (2010) 294:800–9.
20. Mastroiacovo F, Bucci D, Molinaro G, Riozzi B, Pittaluga A, Corsi M, et al. Targeting Group II Metabotropic Glutamate Receptors to Protect SOD-1 Mouse Model of Amyotrophic Lateral Sclerosis. Neurobiol Dis. (2015) 74:126–36. doi: 10.1016/j.nbd.2014.11.012
19. Motolese M, Mastroiacovo F, Cannella M, Bucci D, Gaglione A, Riozzi B, et al. Genetic deletion of mGlu2 metabotropic glutamate receptors improves the short-term outcome of cerebral transient focal ischemia. Mol Brain. (2017) 10:39. doi: 10.1186/s13041-017-0319-6
18. Ciccarelli R, Di Iorio P, Bruno V, Battaglia G, D’Alimonte I, D’Onofrio M, et al. Targeting type-2 metabotropic glutamate receptors to protect the SOD-1 mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. (2015) 74:126–36. doi: 10.1016/j.nbd.2014.11.012
17. Zinni M, Mairesse J, Pansiot J, Fazio F, Iacovelli L, Antenucci N, et al. The role of metabotropic glutamate (mGlu)2 receptor in the neocortex of a mouse model of focal cerebral ischemia. Neuropharmacology: Toxicol Methods. (1999) 27:275–32. doi: 10.1016/S1053-8119(00)00099-9
16. Mastroiacovo et al. mGlu3 Receptors and Brain Ischemia. J Neurol Neurosurg Psychiat. (2007) 78:9594–600. doi: 10.1136/jnnp.50.4.402
15. Landucci E, Boscia F, Gerace E, Scartabelli T, Cozzi A, Moroni F, et al. Induction of the Wnt antagonist, Dickkopf-1, contributes to the development of neuronal death in models of brain focal ischemia. J Cereb Blood Flow Metab. (2009) 29:264–76. doi: 10.1038/jcbfm.2008.111
14. Bao WL, Williams AJ, Faden AI, Tortella FC. Selective mGluR5 receptor antagonists or agonists provide neuroprotection in a rat model of focal cerebral ischemia. Stroke. (2011) 42:39. doi: 10.1161/STROKEAHA.111.649182
13. Rahman MS, Yang J, Luan Y, Qiu Z, Zhang J, Liu H, et al. Attenuation of Acute Endothelin-1-Induced Focal Ischemia in Rats. Neurochem Res. (2020) 45:1230–43. doi: 10.1007/s11064-020-02317-x
12. Backhaus C, Karkoutly C, Welsch M, Kriegstein J. A mouse model of focal cerebral ischemia for screening neuroprotective drug effects. J Pharmacol Toxicol Methods. (1999) 27:275–32. doi: 10.1016/S1053-8119(92)90017-U
11. Madinier A, Quattrorossi MJ, Sjöland C, Ruscher K, Wolich T. Enriched housing enhances recovery of limb placement ability and reduces aggrecan-containing perineuronal nets in the rat somatosensory cortex after experimental stroke. PLoS ONE. (2014) 9:e93121. doi: 10.1371/journal.pone.0093121
10. Riek-Burchardt M, Henrich-Noack P, Reymann KG. No improvement of functional and histological outcome after application of the mGlu1 agonist or antagonist in a rat model of focal cerebral ischemia. Exp Anim. (2009) 58:19–29. doi: 10.1538/expanim.58.19
9. Rahman MS, Yang J, Luan Y, Qiu Z, Zhang J, Liu H, et al. Endothelin-1-induced focal ischemia in rats. Exp Anim. (2009) 55:500–8. doi: 10.1016/j.expert.2008.06.039
8. Motolese M, Mastroiacovo F, Cannella M, Luchenko V, Rajagovska E, Wroblewski JT. Dual neurotoxic and neuroprotective role of metabotropic glutamate receptor1 in conditions of trophic deprivation - possible role as a dependence receptor. Neuropharmacology. (2008) 55:500–8. doi: 10.1016/j.neuropharm.2008.06.039
7. Bao WL, Williams AJ, Faden AI, Tortella FC. Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia. Brain Res. (2001) 922:173–9. doi: 10.1016/S0006-8993(01)03062-1
6. Backhaus C, Karkoutly C, Welsch M, Kriegstein J. A mouse model of focal cerebral ischemia for screening neuroprotective drug effects. J Pharmacol Toxicol Methods. (1999) 27:275–32. doi: 10.1016/S1053-8119(92)90017-U
5. Madinier A, Quattrorossi MJ, Sjöland C, Ruscher K, Wolich T. Enriched housing enhances recovery of limb placement ability and reduces aggrecan-containing perineuronal nets in the rat somatosensory cortex after experimental stroke. PLoS ONE. (2014) 9:e93121. doi: 10.1371/journal.pone.0093121
4. Ricard ML, Prieto I, Franceschi C, Alonso SB, et al. Protective role for type 4 metabotropic glutamate receptors in models of cerebral ischemia. Int Rev Neurobiol. (2009) 85:337–50. doi: 10.1016/S0077-7742(09)50523-X
3. Pellegrini-Giampietro DE. Differential role of mGlu1 and mGlu5 receptors in hippocampal slice models of ischemic tolerance. Eur J Neurosci. (2007) 25:1597–604. doi: 10.1111/j.1465-2448.2007.05614.x
2. Xu W, Wong TP, Cory N, Gaertner T, Wang YT, Baudry M. Calpain-mediated mGluR1alpha truncation: a key step in excitotoxicity. Neuron. (2007) 53:399–412. doi: 10.1016/j.neuron.2006.12.020
1. Pihenichkin S, Dolińska M, Kluzińska M, Luchenko V, Rajagovska E, Wroblewski JT. Dual neurotoxic and neuroprotective role of metabotropic glutamate receptor1 in conditions of trophic deprivation - possible role as a dependence receptor. Neuropharmacology. (2008) 55:500–8. doi: 10.1016/j.neuropharm.2008.06.039
Frontiers in Neurology | www.frontiersin.org 12 June 2021 | Volume 12 | Article 668877
against ischemic brain damage. *J Cereb Blood Flow Metab.* (2011) 31:1107–18. doi: 10.1038/jcbfm.2010.201

41. Fallarino F, Volpi C, Fazio F, Notartomaso S, Vacca C, Busceti C, et al. Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. *Nat Med.* (2010) 16:897–902. doi: 10.1038/nm.2183

42. Pinteaux-Jones F, Sevastou IG, Fry VA, Heales S, Baker D, Pocock AJM. Myelin-induced microglial neurotoxicity can be controlled by microglial metabotropic glutamate receptors. *J Neurochem.* (2008) 106:442–54. doi: 10.1111/j.1471-4159.2008.05426.x

43. Battaglia G, Molinaro G, Rizzoli B, Storto M, Busceti CL, Spinsanti P, et al. Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons. *PLoS ONE.* (2009) 4:e6591. doi: 10.1371/journal.pone.0006591

44. Di Liberto V, Mudò G, Belluardo N. mGluR2/3 agonist activates the transcription factor interferon regulatory factor 1 is expressed after cerebral ischemia and contributes to ischemic brain injury. *J Exp Med.* (1999) 189:719–27. doi: 10.1084/jem.189.7.719

45. Gulyas B, Toth M, Vas A, Shchukin E, Kostulas K, Hillert J, et al. Visualising neuroinflammation in post-stroke patients: a comparative PET study with the TSPO molecular imaging biomarkers [11C]PK11195 and [11C]vinpocetine. *Curr Radiopharm.* (2012) 5:19–28. doi: 10.2174/1874471011205010019

46. Kobayashi K, Imagama S, Ohgomori T, Hirano K, Uchimura K, Sakamoto K, et al. Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. *J Cereb Blood Flow Metab.* (2011) 31:393–402. doi: 10.1038/jcbfm.2010.115

47. Kargbo RB. Allosteric mGluR2/3 modulators for the treatment of psychiatric disorders. *ACS Chem Neurosci.* (2020) 14:66. doi: 10.1021/acschemneuro.9b00619

48. Shichita T, Ito M, Yoshimura A. Post-ischemic inflammation contributes to ischemic brain damage. *J Cereb Blood Flow Metab.* (2011) 31:1107–18. doi: 10.1038/jcbfm.2010.201

49. Villapol S, Faivre V, Joshi P, Moretti R, Besson VC, Charriaut-Marlangue N, et al. Minocycline selectively inhibits M1 polarization of microglia. *JCI Insight.* (2019) 4:e121355. doi: 10.1172/jci.insight.121355

50. Marzolo MP, von Bernhardi R, Inestrosa NC. Mannose receptor is present in microglia/macrophage efferocytosis and inflammation resolution in stroke. *Cell Death and Differ.* (2011) 18:909–18. doi: 10.1038/cdd.2010.154

51. Fenn AM, Henry CJ, Huang Y, Dugan A, Godbout JP. Lipopolysaccharide-induced interleukin (IL)-4 receptor-a expression and corresponding sensitivity to the M2 promoting effects of IL-4 are impaired in microglia of aged mice. *Brain Behav Immun.* (2012) 26:766–77. doi: 10.1016/j.bbi.2011.10.003

52. Cherry JD, Olschowka JA, O’Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. *J Neuroinflammation.* (2014) 11:98. doi: 10.1186/1742-2094-11-98

53. Cai W, Dai X, Chen J, Zhao J, Xu M, Zhang L, et al. ST6/Arg1 promotes microglia/macrophage effectorcytosis and inflammation resolution in stroke mice. *JCI Insight.* (2019) 4:e121355. doi: 10.1172/jci.insight.121355

54. Wolf SA, Boddeke HWGM, Kattenmann H. Microglia in physiology and disease. *Ann Rev Physiol.* (2017) 79:619–43. doi: 10.1146/annurev-physiol-022516-034406

55. Yang SF, Yeh YT, Wang SN, Hung SC, Chen WT, Huang CH, et al. SOCS-3 is associated with vascular invasion and overall survival in hepatocellular carcinoma. *Pathology.* (2008) 40:558–63. doi: 10.1080/00313020802320432

56. Schober A, Peterziel H, von Bartheld CS, Simon H, Kriegstein K, Unsicker K. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action. *Neurobiol Dis.* (2007) 25:378–91. doi: 10.1016/j.nbd.2006.10.005

57. Zölter T, Schneider A, Kleimeyer C, Masuda T, Petru PS, Pfeifer D, et al. Silencing of TGFβ-signalling in microglia results in impaired homeostasis. *Nat Commun.* (2018) 9:4011. doi: 10.1038/s41467-018-06224-y

58. van Ehr A, Attai A, Neidert N, Petru PS, Ruß T, Zölter T, et al. Inhibition of Microglial TGFβ Signaling Increases Expression of Mrc1. *Front Cell Neurosci.* (2020) 14:66. doi: 10.3389/fncell.2020.00066

59. Monn JA, Henry SS, Massey SM, Clawson DK, Chen Q, Diseroad BA. Synthesis and pharmacological characterization of C4-β-amide-substituted 2-amino-3-(3-hexyl-2,6-dicarboxylates. Identification of (S,2S,4S,5R,6S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY2794193), a Highly Potent and Selective mGluR4 Agonist. *J Med Chem.* (2020) 63:5686–71. doi: 10.1021/acs.jmedchem.9b01525

60. Schober A, Peterziel H, von Bartheld CS, Simon H, Kriegstein K, Unsicker K. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action. *Neurobiol Dis.* (2007) 25:378–91. doi: 10.1016/j.nbd.2006.10.005

61. Kargbo RB. Allosteric mGluR2/3 modulators for the treatment of psychiatric disorders. *ACS Chem Lett.* (2019) 10:145–6. doi: 10.1021/acschemlett.8b00619

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Mastroiacovo, Zinni, Mascio, Bruno, Battaglia, Pansiot, Imbriglio, Mairesse, Baud and Nicoletti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.